Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands - Allison, Simon J.; Sadiq, Maria; Baronou, Efstathia; Cooper, Patricia A.; Dunnill, Chris; Georgopoulos, Nikolaos T.; Latif, Ayşe; Shepherd, Samantha; Shnyder, Steve D.; Stratford, Ian J.; Wheelhouse, Richard T.; Willans, Charlotte E.; et al. (Cancer letters, 2017)
Keywords: Antigens, Neoplasm - metabolism; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - toxicity; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Apoptosis - drug effects; Cancer; Cancer therapies; Cell death; Cell Line, Tumor; Cell Survival - drug effects; Cisplatin; Cisplatin - pharmacology; Cytotoxicity; Dacarbazine - analogs & derivatives; Dacarbazine - pharmacology; Deoxyribonucleic acid; DNA; DNA Damage; DNA repair; DNA topoisomerase; DNA Topoisomerases, Type I - metabolism; DNA Topoisomerases, Type II - metabolism; DNA-Binding Proteins - metabolism; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow cytometry; Glycolysis; Glycolysis - drug effects; Glycolytic inhibitor; Gold; Hematology, Oncology and Palliative Medicine; Humans; Imidazoles - chemistry; Imidazoles - pharmacology; Imidazoles - toxicity; Inhibitory Concentration 50; Kinases; Ligands; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Organometallic complexes; Organometallic Compounds - chemistry; Organometallic Compounds - pharmacology; Organometallic Compounds - toxicity; Oxidative Stress - drug effects; PARP1 inhibitor; Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors; Poly (ADP-Ribose) Polymerase-1 - metabolism; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Reactive oxygen species; Reactive Oxygen Species - metabolism; Reductase; Signal Transduction - drug effects; Silver; Silver-N-heterocyclic carbene; Temozolomide; Thioredoxin; Thioredoxin Reductase 1 - antagonists & inhibitors; Thioredoxin Reductase 1 - metabolism; Thioredoxin reductase inhibitor; Topoisomerase I Inhibitors - pharmacology; Topoisomerase II Inhibitors - pharmacology; Topoisomerase inhibitor; Tumors; Thioredoxin reductase inhibitor; Silver-N-heterocyclic carbene; PARP1 inhibitor; Topoisomerase inhibitor; Glycolytic inhibitor; Silver- N-heterocyclic carbene